Catalyst Pharma: Vamorolone Phase 1 shows glucocorticoid activity without immunosuppression at clinical doses

CATALYST PHARMACEUTICALS, INC.

Phase 1 study: vamorolone 300 mg vs deflazacort 0.9 mg/kg showed comparable cortisol suppression.
No significant immunosuppressive effects at clinical doses (9 or 27 mg/kg/day); only at 40 mg/kg/day.
Data support current vamorolone dosing in DMD and potential for broader chronic inflammatory indications.
Study enrolled 24 healthy adults (Part A) and 36 volunteers (Part B) with ascending doses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.